NYSE:GKOS Glaukos - GKOS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Glaukos Co. Please log in to your account or sign up in order to add this asset to your watchlist. $49.35 +1.14 (+2.36%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$47.80▼$49.5850-Day Range$45.25▼$52.4852-Week Range$33.33▼$64.49Volume289,068 shsAverage Volume473,904 shsMarket Capitalization$2.36 billionP/E RatioN/ADividend YieldN/APrice Target$56.67 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Glaukos MarketRank™ ForecastAnalyst RatingModerate Buy2.56 Rating ScoreUpside/Downside14.8% Upside$56.67 Price TargetShort InterestBearish10.30% of Float Sold ShortDividend StrengthN/ASustainability-0.90Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.38) to ($1.84) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.91 out of 5 starsMedical Sector726th out of 1,005 stocksSurgical & Medical Instruments Industry71st out of 102 stocks 3.3 Analyst's Opinion Consensus RatingGlaukos has received a consensus rating of Buy. The company's average rating score is 2.56, and is based on 5 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $56.67, Glaukos has a forecasted upside of 14.8% from its current price of $49.35.Amount of Analyst CoverageGlaukos has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 0.0 Short Interest Percentage of Shares Shorted10.30% of the float of Glaukos has been sold short.Short Interest Ratio / Days to CoverGlaukos has a short interest ratio ("days to cover") of 11.8, which indicates bearish sentiment.Change versus previous monthShort interest in Glaukos has recently increased by 5.59%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGlaukos does not currently pay a dividend.Dividend GrowthGlaukos does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGlaukos has received a 65.97% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical laser systems", "Medical technology engineering", and "Surgical instruments" products. See details.Environmental SustainabilityThe Environmental Impact score for Glaukos is -0.90. Previous Next 2.0 News and Social Media Coverage News SentimentGlaukos has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Glaukos this week, compared to 3 articles on an average week.Search Interest1 people have searched for GKOS on MarketBeat in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Glaukos insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.10% of the stock of Glaukos is held by insiders.Percentage Held by Institutions92.17% of the stock of Glaukos is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Glaukos are expected to grow in the coming year, from ($2.38) to ($1.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Glaukos is -23.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Glaukos is -23.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGlaukos has a P/B Ratio of 4.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Glaukos (NYSE:GKOS) StockGlaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in San Clemente, CA.Read More Receive GKOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Glaukos and its competitors with MarketBeat's FREE daily newsletter. Email Address GKOS Stock News HeadlinesMarch 21, 2023 | americanbankingnews.comGlaukos Co. (NYSE:GKOS) Given Average Recommendation of "Hold" by BrokeragesFebruary 27, 2023 | finance.yahoo.comGlaukos Submits New Drug Application to U.S. FDA for iDose TRMarch 26, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.February 27, 2023 | finance.yahoo.comForeign Currency Headwinds Dragged Glaukos Corporation (GKOS) Shares in Q4February 24, 2023 | finance.yahoo.comGlaukos Full Year 2022 Earnings: Revenues Beat Expectations, EPS LagsFebruary 23, 2023 | finance.yahoo.comGlaukos' (GKOS) Q4 Earnings Beat Estimates, Sales Decline Y/YFebruary 22, 2023 | finance.yahoo.comGlaukos Announces Fourth Quarter and Full Year 2022 Financial ResultsFebruary 15, 2023 | finance.yahoo.comGlaukos Announces Participation in the Citi Healthcare ConferenceMarch 26, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. February 12, 2023 | finance.yahoo.comGlaukos Corporation (GKOS) Stock Historical Prices & Data - Yahoo FinanceFebruary 1, 2023 | finance.yahoo.comGlaukos to Release Fourth Quarter and Full Year 2022 Financial Results after Market Close on February 22January 12, 2023 | seekingalpha.comGlaukos sees positive data from mid-stage trial of dry eye treatmentJanuary 10, 2023 | finance.yahoo.comGlaukos Announces Positive Results for iDose TR Exchange Trial, Highlighting Favorable Safety and TolerabilityJanuary 10, 2023 | finance.yahoo.comGlaukos Announces Positive Clinical Updates for Several Corneal Health Pipeline ProgramsDecember 28, 2022 | finance.yahoo.com3 Reasons to Retain Glaukos (GKOS) Stock in Your PortfolioDecember 2, 2022 | finance.yahoo.comGlaukos (GKOS) Up 0.8% Since Last Earnings Report: Can It Continue?November 26, 2022 | finance.yahoo.comDespite currently being unprofitable, Glaukos (NYSE:GKOS) has delivered a 79% return to shareholders over 5 yearsNovember 7, 2022 | finance.yahoo.comHere's Why Glaukos (GKOS) Could be Great Choice for a Bottom FisherNovember 7, 2022 | finance.yahoo.comGlaukos Announces Participation in the Stephens Annual Investment ConferenceNovember 3, 2022 | finance.yahoo.comGlaukos (GKOS) Beats on Q3 Earnings, Tightens Sales ViewNovember 2, 2022 | finance.yahoo.comGlaukos Corporation Announces Third Quarter 2022 Financial ResultsOctober 26, 2022 | finance.yahoo.comGlaukos (GKOS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?October 14, 2022 | nasdaq.comOrthofix (OFIX) Soars 5%: Is Further Upside Left in the Stock? - NasdaqOctober 14, 2022 | streetinsider.comGlaukos to Release Third Quarter 2022 Financial Results after Market Close on November 2 - StreetInsider.comOctober 13, 2022 | streetinsider.comStephens Resumes Glaukos Corporation (GKOS) at Overweight - StreetInsider.comOctober 13, 2022 | nasdaq.comNotable Two Hundred Day Moving Average Cross - GKOS - NasdaqOctober 12, 2022 | finance.yahoo.comGlaukos to Release Third Quarter 2022 Financial Results after Market Close on November 2 - Yahoo FinanceSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive GKOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Glaukos and its competitors with MarketBeat's FREE daily newsletter. Email Address GKOS Company Calendar Last Earnings2/22/2023Today3/26/2023Next Earnings (Estimated)5/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNYSE:GKOS CUSIPN/A CIK1192448 Webwww.glaukos.com Phone(949) 367-9600Fax949-367-9984Employees727Year FoundedN/APrice Target and Rating Average Stock Price Forecast$56.67 High Stock Price Forecast$68.00 Low Stock Price Forecast$44.00 Forecasted Upside/Downside+14.8%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-99,190,000.00 Net Margins-35.07% Pretax Margin-34.80% Return on Equity-18.51% Return on Assets-10.12% Debt Debt-to-Equity Ratio0.67 Current Ratio6.13 Quick Ratio5.61 Sales & Book Value Annual Sales$282.86 million Price / Sales8.35 Cash FlowN/A Price / Cash FlowN/A Book Value$11.11 per share Price / Book4.44Miscellaneous Outstanding Shares47,880,000Free Float44,000,000Market Cap$2.36 billion OptionableOptionable Beta1.24 Key ExecutivesThomas William BurnsChairman & Chief Executive OfficerJoseph E. GilliamPresident & Chief Operating OfficerAlex ThurmanChief Financial Officer & Senior Vice PresidentJay L. KatzChief Medical OfficerDiane W. BiagiantiSenior Vice President & General CounselKey CompetitorsTandem Diabetes CareNASDAQ:TNDMNuVasiveNASDAQ:NUVAAxonicsNASDAQ:AXNXAtriCureNASDAQ:ATRCAlphatecNASDAQ:ATECView All CompetitorsInsiders & InstitutionsMetLife Investment Management LLCSold 896 shares on 3/23/2023Ownership: 0.050%Voya Investment Management LLCBought 4,737 shares on 2/28/2023Ownership: 0.098%Teachers Retirement System of The State of KentuckyBought 1,655 shares on 2/22/2023Ownership: 0.074%Macquarie Group Ltd.Bought 22,054 shares on 2/21/2023Ownership: 0.047%Truist Financial CorpSold 2,661 shares on 2/17/2023Ownership: 0.077%View All Insider TransactionsView All Institutional Transactions GKOS Stock - Frequently Asked Questions Should I buy or sell Glaukos stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last twelve months. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GKOS shares. View GKOS analyst ratings or view top-rated stocks. What is Glaukos' stock price forecast for 2023? 9 Wall Street research analysts have issued 12-month price targets for Glaukos' shares. Their GKOS share price forecasts range from $44.00 to $68.00. On average, they predict the company's stock price to reach $56.67 in the next year. This suggests a possible upside of 14.8% from the stock's current price. View analysts price targets for GKOS or view top-rated stocks among Wall Street analysts. How have GKOS shares performed in 2023? Glaukos' stock was trading at $43.68 at the start of the year. Since then, GKOS shares have increased by 13.0% and is now trading at $49.35. View the best growth stocks for 2023 here. Are investors shorting Glaukos? Glaukos saw a increase in short interest in February. As of February 28th, there was short interest totaling 4,720,000 shares, an increase of 5.6% from the February 13th total of 4,470,000 shares. Based on an average trading volume of 398,600 shares, the days-to-cover ratio is presently 11.8 days. Currently, 10.3% of the company's stock are sold short. View Glaukos' Short Interest. When is Glaukos' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023. View our GKOS earnings forecast. How were Glaukos' earnings last quarter? Glaukos Co. (NYSE:GKOS) announced its quarterly earnings data on Wednesday, February, 22nd. The medical instruments supplier reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.03. The medical instruments supplier earned $71.23 million during the quarter, compared to analyst estimates of $67.71 million. Glaukos had a negative net margin of 35.07% and a negative trailing twelve-month return on equity of 18.51%. What ETFs hold Glaukos' stock? ETFs with the largest weight of Glaukos (NYSE:GKOS) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Health Care Equipment ETF (XHE), ROBO Global Healthcare Technology and Innovation ETF (HTEC), Principal Healthcare Innovators ETF (BTEC), Xtrackers S&P SmallCap 600 ESG ETF (SMLE), SPDR S&P SmallCap 600 ESG ETF (ESIX), SPDR S&P 600 Small Cap Growth ETF (SLYG) and iShares S&P Small-Cap 600 Growth ETF (IJT). What guidance has Glaukos issued on next quarter's earnings? Glaukos issued an update on its FY 2023 earnings guidance on Wednesday, February, 22nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $290.00 million-$295.00 million, compared to the consensus revenue estimate of $304.65 million. What is Thomas W. Burns' approval rating as Glaukos' CEO? 10 employees have rated Glaukos Chief Executive Officer Thomas W. Burns on Glassdoor.com. Thomas W. Burns has an approval rating of 100% among the company's employees. This puts Thomas W. Burns in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Glaukos own? Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include NVIDIA (NVDA), Marvell Technology (MRVL), PTC Therapeutics (PTCT), PayPal (PYPL), QUALCOMM (QCOM), Alibaba Group (BABA), Teladoc Health (TDOC), Intel (INTC), Advanced Micro Devices (AMD) and Boeing (BA). When did Glaukos IPO? (GKOS) raised $76 million in an initial public offering on Thursday, June 25th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs acted as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers. What is Glaukos' stock symbol? Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS." Who are Glaukos' major shareholders? Glaukos' stock is owned by a number of institutional and retail investors. Top institutional investors include Artisan Partners Limited Partnership (3.99%), Braidwell LP (3.48%), Fred Alger Management LLC (2.78%), Point72 Asset Management L.P. (2.42%), Geode Capital Management LLC (1.74%) and Morgan Stanley (1.70%). Insiders that own company stock include Gilbert H Kliman, Joseph E Gilliam, Thomas William Burns and William J Phd Link. View institutional ownership trends. How do I buy shares of Glaukos? Shares of GKOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Glaukos' stock price today? One share of GKOS stock can currently be purchased for approximately $49.35. How much money does Glaukos make? Glaukos (NYSE:GKOS) has a market capitalization of $2.36 billion and generates $282.86 million in revenue each year. The medical instruments supplier earns $-99,190,000.00 in net income (profit) each year or ($2.09) on an earnings per share basis. How many employees does Glaukos have? The company employs 727 workers across the globe. How can I contact Glaukos? Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The official website for the company is www.glaukos.com. The medical instruments supplier can be reached via phone at (949) 367-9600, via email at investors@glaukos.com, or via fax at 949-367-9984. This page (NYSE:GKOS) was last updated on 3/26/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.